Clinical Trial

A Study of RAY1225 in Participants With Type 2 Diabetes

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 5, 2025 (before its estimated December 20, 2025 completion). Its status may not reflect the trial's current state.
Summary
The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with type 2 diabetes mellitus. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-02-03; most recent amendment 2025-08-04.
Status change: Recruiting → Active, Not Recruiting 2025-08-04
Status change: Not Yet Recruiting → Recruiting 2024-02-28
Trial Details
NCT Number NCT06254274
Lead Sponsor Guangdong Raynovent Biotech Co., Ltd
Conditions T2DM (Type 2 Diabetes Mellitus)
Enrollment 210 participants
Start Date 2024-02-26
Primary Completion 2025-12-20 (estimated)
Study Completion 2025-12-20 (estimated)
Updated on ClinicalTrials.gov 2025-08-05